Expression of minichromosome maintenance protein 2 as a marker for proliferation and prognosis in diffuse large B-cell lymphoma: a tissue microarray and clinico-pathological analysis
verfasst von:
Ellen C Obermann, Philip Went, Annette Zimpfer, Alexandar Tzankov, Peter J Wild, Robert Stoehr, Stefano A Pileri, Stephan Dirnhofer
Minichromosome maintenance (MCM) proteins are essential for the initiation of DNA replication and have been found to be relevant markers for prognosis in a variety of tumours. The aim of this study was to assess the proliferative activity of diffuse large B-cell lymphoma (DLBCL) in tissue microarray (TMA) using one of the minichromosome maintenance proteins (Mcm2) and to explore its potential value to predict prognosis.
Methods
Immunohistochemistry for Mcm2 was performed on TMAs constructed from 302 cases of DLBCL. A monoclonal mouse antibody was used after heat induced antigen retrieval. Mcm2 expression was scored quantitatively. Positivity for Mcm2 was defined as presence of nuclear expression of Mcm2 in greater than or equal to 40 % of tumour cells. A statistical analysis was carried out of the association of Mcm2 and the clinico-pathological characteristics.
Results
Mcm2 expression was clearly evident in the nuclei of proliferating non-neoplastic cells and tumour cells. Positivity for Mcm2 was found in 46% (98/211) of analysable cases. A significant correlation existed between Mcm2 expression and presence of bulky disease (p = 0.003). Poor disease specific survival was observed in patients with DLBCL positive for Mcm2 expression in the univariate analysis (p = 0.0424).
Conclusion
Mcm2 expression can be used to assess tumour proliferation and may be useful as an additional prognostic marker to refine the prediction of outcome in DLBCL.
The online version of this article (doi:10.1186/1471-2407-5-162) contains supplementary material, which is available to authorized users.
Competing interests
The author(s) declare that they have no competing interests.
Authors' contributions
ECO conceived and designed the study, was responsible for immunohistochemical studies and drafted the manuscript. PW, AZ, AT and SAP were responsible for acquisition of material and clinical data as well as construction of tissue microarrays. PJW performed the statistical analysis, helped to prepare figures and tables and interpreted the data. RS revised the article critically. SD participated in the design and coordination of the study. All authors read and approved the final manuscript.
Background
In Western countries, diffuse large B-cell lymphoma (DLBCL) is the most common type of mature B-cell lymphomas with a frequency of approximately 30 to 40% [1]. DLBCL is an aggressive but potentially curable disease. However, only about 40 to 45% of patients are cured with combination chemotherapy [2]. Currently, the International Prognostic Index (IPI) is the generally accepted predictor of prognosis [3]. In order to avoid over-treatment of some patients and identify patients at high-risk for early relapse or poor response to standard treatment, individualised prediction of prognosis becomes more and more important.
A number of biological markers have been studied for their predictive potential, but none has become universally accepted [4‐7]. Gene expression profiling has helped to identify at least two subgroups of DLBCL, one with a germinal centre signature and the other with an activated B-cell signature, which show distinct clinical outcomes [3, 8].
Anzeige
The proliferative capacity of neoplastic cells is an important feature of growing tumours. Assessment of cell proliferation may provide both pathologists and clinicians with more objective prognostic information [9, 10]. Expression of Ki-67 as assessed by immunohistochemistry has become the standard proliferation marker [11‐13]. In lymphoid neoplasms, it is controversial whether Ki-67 is a reliable prognostic indicator [14‐17]. In DLBCL, a high proliferation index has been associated with an unfavourable clinical outcome in some studies [18]. Despite the extensive use of Ki-67, its functional significance still remains unclear [19]. It has been suggested, that Ki-67 plays a role in the ribosome biosynthesis rather than being directly responsible for cell proliferation [20, 21]. Therefore, detecting markers directly involved in DNA replication might be a more precise method to evaluate the proliferative behaviour of a tumour.
The minichromosome maintenance (MCM) protein family consists of six members of DNA-binding proteins [22]. MCM proteins stand at the end of many signalling pathways involved in cell proliferation [23]. They ensure that synthesis of DNA is initiated only once during each cell cycle. All six proteins are abundant throughout the cell cycle and are broken down rapidly on differentiation or more slowly in quiescence [24, 25]. Expression is only observed in cycling cells, there is no expression in quiescent and differentiating cells [25‐28].
Antibodies for detection of MCM proteins in routinely processed tissue specimen have been found superior to Ki-67 in defining the proliferative compartments in both normal and abnormal human tissues [27, 29‐32]. Immunohistochemical assessment of all six MCM proteins has been observed to produce similar results in a range of tissue sections [33]. MCM proteins have been promoted as markers for cancer screening, surveillance and prognosis [27, 29‐31, 34‐36]. We used a specific monoclonal antibody directed against Mcm2 and a previously validated tissue microarray (TMA) with tissue samples of a large number of DLBCL [37]. Tissue microarrays are highly efficient for the investigation of large series of neoplasms including lymphoma [37‐39].
The aim of this study was to systematically investigate if the analysis of Mcm2 expression might provide a novel tool to assess the proliferation of DLBCL and predict clinical outcome in patients with this disease.
Anzeige
Methods
Construction of tissue microarrays and acquisition of clinico-pathologic data
Tissue microarrays were constructed as described previously [39, 40]. The TMAs contained a total of 302 tissue samples from tumours, which had been classified prior to this study as diffuse large B-cell lymphomas according to the WHO classification [1]. All samples had been obtained at the time of diagnosis, before any treatment had been given. Four different TMAs were constructed, each containing tumour samples from different histopathologic institutions (Basel, Bologna, Innsbruck, Zurich). Clinical data of patients with DLBCL at time of primary diagnosis and follow-up had been obtained by reviewing the charts. Clinico-pathologic data of patients at time of diagnosis are detailed in table 1. Retrieval of tissue and clinical data was performed according to the regulations of the local institutional review board and data safety laws.
Table 1
Details of clinico-pathologic data and expression of Mcm2 in diffuse large B-cell lymphomas
Variable
Categorisation
n analysable
%
Clinico-pathologic data:
Age at diagnosis
median 67 years (interquartile range 54–75 years)
<65 years
69
43.1
≥65 years
91
56.9
Gender
male
97
53.3
female
85
46.7
Ann Arbor stage
1
27
17.3
2
50
32.1
3
34
21.8
4
45
28.8
International prognostic index (IPI)
0
2
1.3
1
66
43.4
2
29
19.1
3
32
21.1
4
23
15.1
Bone marrow involvement
yes
44
28.6
no
110
71.4
Extranodal involvement
yes
54
35.8
no
97
64.2
Bulky disease
yes
94
64.4
no
52
35.6
Chemotherapy
no therapy
7
4.6
CHOP
69
45.1
other
77
50.3
Serum levels of LDH at diagnosis
median 306 U/l (interquartile range 185–443 U/l)
<300 U/l
61
49.2
≥300 U/l
63
50.8
Immunohistochemistry:
Mcm2 immunoreactivity
median 38% (interquartile range 29%–48%)
<40%
113
53.6
≥40%
98
46.4
Immunohistochemistry
Four-micrometre sections of the TMA blocks were cut to adhesive-coated slides (Instrumedics Inc, Hackensack, NJ, USA) and stained using standard procedures. Briefly, immunohistochemical studies utilized an avidin-biotin peroxidase method with diaminobenzidine chromatogen. After heat induced antigen retrieval (microwave oven for 30 min at 250 W) immunohistochemistry was carried out in a NEXES immunostainer (Ventana, Tucson, AZ). The following primary antibody was used: BM28 (mouse monoclonal, clone 46, BD Biosciences, San Jose, US, final dilution 1:3000). The dilution had been established using adequate controls. Negative controls were obtained by omitting the primary antibody. The slides were evaluated without knowledge of clinical data. At least 10% of cases were re-evaluated by a second observer. Only cases containing clearly recognisable tumour tissue were analysed. One-hundred cells were assessed in each tumour core and the percentage of positive cells (i.e. cells with a distinct staining) was calculated. If a biopsy core contained less than 100 cells as many neoplastic cells as possible were evaluated. If more than one core from the same tumour was available the results were averaged. Cases were defined positive for Mcm2 if ≥40 % of tumours cells showed distinct nuclear staining. The determination of cut-off levels was based on the analysis of the area under the receiver operating characteristic curve (AUROC) as described below and as detailed in table 2.
Table 2
Performance of metric variables in prediction of mortality using the AUROC (area under the receiver operating characteristic curve) method
Mcm2 IHCc
LDHd
Optimum cutoff value
39.5%
306 U/l
Sensitivityb
0.512
0.620
Specificityb
0.696
0.476
AUROCa
0.582
0.553
95% confidence interval
0.462–0.702
0.434–0.672
p (asymtptotic significance)
0.182
0.384
a AUROC, area under the receiver operating characteristic curve.
b sensitivity and specificity were calculated for the cutoff, which represented the best discrimination as derived from the ROC curves.
c IHC: immunohistochemistry
d LDH: lactate dehydrogenase
Statistical analysis
Statistical analyses were performed using SPSS version 10.0 (SPSS, Chicago, IL). Differences were considered statistically significant if P values were <0.05. Receiver operating characteristic (ROC) curves by plotting sensitivity versus (1-specificity) were used to evaluate the diagnostic performance of parameters at various cut-off points. An AUROC closer to 1 indicates greater discriminatory power, whereas an AUROC of 0.5 denotes no diagnostic potential. The optimum cut-off was calculated as the maximum value of sensitivity multiplied by specificity. Sensitivity and specificity were calculated according to standard formulas for the cut-off that represented the best discrimination derived from the ROC curves. The cut-off value representing the best discrimination derived from the ROC analysis was chosen for categorization of metric variables (LDH (lactate dehydrogenase) and expression of Mcm2). A statistical association between clinico-pathologic parameters and Mcm2 expression was tested using a two-sided Fisher's exact test. Disease specific survival (DSS) curves were calculated using the Kaplan-Meier method with significance evaluated by two-sided log-rank statistics. For DSS analysis, patients were censored at the time of their last clinical follow-up appointment or at their date of death not related to the tumour. A stepwise multivariable Cox regression model was adjusted, testing the independent prognostic relevance of Mcm2 positivity. The limit for reverse selection procedures was P = 0.1. The proportionality assumption for all variables was assessed with log-negative-log survival distribution functions.
Results
Clinico-pathologic data
Clinical follow-up data were available for 123 of 302 (40.7 %) patients with a median follow-up period of 23.5 months (range 1 to 177 months). The median follow-up for censored patients was 28.5 months. Clinico-pathologic parameters associated with poor disease specific survival were Ann Arbor stage (p = 0.0026), IPI (p < 0.0001), and serum LDH ≥300 U/l (p = 0.0133) according to the univariate analysis. The optimum cut-off level for LDH had been established at 306 U/l (AUROC method) and a cut-off of 300 U/l was used for further statistical analysis. Age at diagnosis and gender of patients did not make an impact on DSS. Neither the presence of bone marrow involvement, extranodal involvement nor bulky disease at presentation was statistically relevant for DSS.
The results of the univariate analysis are presented in table 3.
Table 3
Univariate analysis of factors regarding disease specific survival
Tumor-related death
Variable
Categorisation
n
events
pa
Clinico-pathologic data:
Age at diagnosis
<65 years
44
20
0.0805
≥65 years
77
43
Gender
male
64
31
0.4220
female
59
34
Ann Arbor Stage
1
19
6
0.0026
2
37
16
3
27
15
4
39
27
International prognostic index
0
2
0
<0.0001
1
46
16
2
24
11
3
25
20
4
22
16
Extranodal involvement
no
47
24
0.9997
yes
70
36
Bulky disease
no
73
36
0.3135
yes
39
20
Serum levels of LDH at diagnosis
<300 U/l
38
19
0.0133
≥300 U/l
54
31
Immunohistochemistry:
Mcm2 immunoreactivity
<40%
52
21
0.0424
≥40%
36
22
a Log rank test; bold face representing significant data.
Immunohistochemistry
Investigation of Mcm2 expression was informative in 69.9 % (211/302) of cases. Mcm2 expression in ≥40% of cells was detected in 46.4 % (98/211) of DLBCL. Mcm2 was clearly evident in the nuclei of tumour cells with low background staining. In non-neoplastic lymphoid tissue, which was used as a positive control and for establishing the appropriate staining protocols, expression of Mcm2 was mainly found in the germinal centres harbouring proliferating cells; expression in the mantle zone and parafollicular zone was negligible (Figure 1A). Identical results have previously been described [41].
×
The optimum cut-off for Mcm2 expression was calculated as 39.5 % of cells using the AUROC method. For practical reasons, a cut-off level of 40 % was chosen and patients were divided into two subgroups accordingly (positive: protein expression ≥40 % of cells; negative: protein expression <40 % of cells). For descriptive data analysis, all relevant variables were compared with Mcm2 expression (table 4). A representative image of immunohistochemical expression of Mcm2 in DLBCL is shown in figure 1B.
Table 4
Clinico-pathologic and immunohistochemical parameters in relation to Mcm2 immunoreactivity
Mcm2 immunoreactivity
Variable
Categorisation
n analysable
negative (<40%)
positive (≥40%)
pa
Clinico-pathologic data:
Age at diagnosis
<65 years
47
27
20
1.000
≥65 years
63
37
26
Gender
male
72
39
33
0.593
female
57
34
23
Ann Arbor Stage
1
15
10
5
0.342
2
34
15
19
3
23
14
9
4
35
22
13
International prognostic index
0
2
2
0
0.122
1
48
27
21
2
21
14
7
3
20
13
7
4
14
4
10
Bone marrow involvement
no
72
39
33
0.414
yes
35
22
13
Extranodal involvement
no
40
27
13
0.103
yes
62
31
31
Bulky disease
no
62
44
20
0.003
yes
35
13
22
Serum levels of LDH at diagnosis
<300 U/l
42
23
19
0.505
≥300 U/l
41
26
15
a two-sided Fisher's exact test; bold type representing significant data.
Prognostic significance
Disease specific survival was compared between tumours positive and negative for Mcm2 by univariate log-rank statistics. Positivity for Mcm2 was associated with shorter DSS (p = 0.0424) (table 3; figure 2). However, when Mcm2 positivity was tested in the multivariate analysis in combination with LDH, IPI, and Ann Arbor stage it did not retain its prognostic value (p = 0.546). LDH was not found to be of prognostic relevance in the multivariate analysis as well (p = 0.063). Both IPI (p = 0.010) and Ann Arbor stage (p = 0.025) were significant prognostic markers in the multivariate analysis with respect to disease specific survival.
×
Anzeige
Discussion
Cell proliferation is essential for the growth of any type of malignancy. Analysis of cell proliferation applying antibodies specifically detecting members of the MCM protein family has been proposed as a novel method for cell cycle assessment which may be of diagnostic and prognostic value in the histopathologic assessment of neoplasms. Other proliferation markers such as the widely used Ki-67 and proliferating cell nuclear antigen (PCNA) are probably not as effective as MCM proteins for this purpose, as Ki-67 is absent in early G1-phase, its function still remains unknown [42] and PCNA is less specific for determining proliferation since it is also present during DNA repair processes [43].
Analysis of MCM proteins by means of immunohistochemistry has been shown to be of prognostic value in a diverse range of human malignancies [30, 34, 44‐51]; in lymphoma however, high expression of Mcm2 has been described in DLBCL, but so far data have never been evaluated with respect to clinical outcome [41].
Therefore we focused on the evaluation of Mcm2 expression in a large collective of clinically well documented patients with DLBCL using tissue microarray technology and immunohistochemistry. 46.4% of DLBCL showed positivity for Mcm2 defined as expression in ≥40% of tumour cells. Positivity was significantly associated with shorter disease specific survival in the univariate analysis (p = 0.0424). However, when tested in the multivariate analysis, it did not retain its prognostic value (p = 0.546). This finding may be attributable to the fact, that besides proliferation, a number of other factors not included into the clinico-pathological parameters of our analysis (such as concomitant morbidity) may influence disease specific survival. Therefore, assessment of Mcm2 expression may still be useful as an additional prognostic marker in conjunction with other established prognostic parameters.
Conclusion
In summary, expression of Mcm2 in ≥40% of tumour cells was found to be a negative prognostic marker for disease specific survival in this large series of DLBCL. Protein expression of MCM proteins can easily be evaluated in routinely processed tissue specimen using specific antibodies in daily routine practice. Assessment of MCM protein expression may be used as a marker of proliferation as well as a potentially prognostic indicator, and further work in this area is warranted.
Anzeige
Acknowledgements
The authors thank A Vielberth, H Weisskopf and R Epper for excellent technical assistance. Prof. F Hofstaedter, head of the Institute of Pathology, University of Regensburg, is acknowledged for his continuous support. Prof. G Jundt, head of the cancer registry Basel, is acknowledged for providing clinical data. Caroline Selai, PhD, University College London, is gratefully acknowledged; without her encouragement, this study would never have been undertaken. This study was supported by a grant of the University of Regensburg to ECO (Regensburger Forschungsförderung in der Medizin).
Open Access
This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution License (
https://creativecommons.org/licenses/by/2.0
), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Competing interests
The author(s) declare that they have no competing interests.
Authors' contributions
ECO conceived and designed the study, was responsible for immunohistochemical studies and drafted the manuscript. PW, AZ, AT and SAP were responsible for acquisition of material and clinical data as well as construction of tissue microarrays. PJW performed the statistical analysis, helped to prepare figures and tables and interpreted the data. RS revised the article critically. SD participated in the design and coordination of the study. All authors read and approved the final manuscript.
Expression of minichromosome maintenance protein 2 as a marker for proliferation and prognosis in diffuse large B-cell lymphoma: a tissue microarray and clinico-pathological analysis
verfasst von
Ellen C Obermann Philip Went Annette Zimpfer Alexandar Tzankov Peter J Wild Robert Stoehr Stefano A Pileri Stephan Dirnhofer
Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.
Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.
Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.
Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.
Update Onkologie
Bestellen Sie unseren Fach-Newsletterund bleiben Sie gut informiert.